FERN – Announces Off-Grid Solar Initiative

Jul 11, 2017
OTC Disclosure & News Service

Fountain Hills, AZ –

FERN – Announces Off-Grid Solar Initiative

Fountain Hills, AZ (July 11, 2017) Fernhill Corporation. (OTC PINK: FERN)

Fernhill Corporation is pleased to announce its strategy to launch a new line of off-grid solar products under the current corporate structure.

This initiative will enable Fernhill to design, develop and create a suite of custom off-grid solar solutions moving forward. The proposed new products will be tailored to meet the special demands of clientele in this rapidly growing industry.

Currently, the specialty market and off-grid manufacturing sector is a relatively untapped space that is not in the scope of large tier manufacturers. These off-grid products can provide lucrative margins from a market that does not have a steady supply of readily available products. Moving forward, Fernhill Corporation plans to develop a suite of solutions that can be integrated into electric vehicles, power storage units, and other recreational products. Having the ability to create practical solutions for off-grid products will allow Fernhill to expand its operations and take advantage of this emerging sector.

Management will continue to update shareholders with further advancements to these projects as they develop.

About Fernhill Corporation

Fernhill Corporation is a parent company that exploits new products, technologies and or opportunities. Incorporated in Nevada with operations in North America, Fernhill Corporation is focused on acquisitions and or partnerships in the energy and technology sectors.

Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Adam Kovacevic

adam@fernhillcorp.com

Contact:

Daniel Wong

Omnivance Advisors, Inc.

Dan@omnivanceadvisors.com

858.381.5740

This release includes additional documents. Select the link(s) below to view.

FERN – Announces Off-Grid Solar Initiative.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Fernhill Corporation Announces Acquisition of Solar Technology Companys

Jul 06, 2017
OTC Disclosure & News Service

Fountain Hills, AZ –

FERN – Announces Acquisition of Solar Technology Company

Fountain Hills, AZ (July 5, 2017) Fernhill Corporation. (OTC PINK: FERN)

Fernhill Corporation is pleased to report that on June 30th, 2017 the company has entered into a definitive agreement where Fernhill Corporation will acquire 100% interest in Worldwide Sun an Arizona Limited Liability Company.

Worldwide Suns extensive experience, both in the development and testing of specialty off grid solar products will prove to be a valuable asset to the corporation moving forward. The associated intellectual property will expand the corporations’ ability to develop and market a full suite of custom off grid solar solutions and consumer solar products.

About Fernhill Corporation

Fernhill Corporation is a parent company that exploits new products, technologies and or opportunities. Incorporated in Nevada with operations in North America, Fernhill Corporation is focused on acquisitions and or partnerships in the energy and technology sectors.

Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Adam Kovacevic

adam@fernhillcorp.com

Contact:

Daniel Wong

Omnivance Advisors, Inc.

Dan@omnivanceadvisors.com

858.381.5740

This release includes additional documents. Select the link(s) below to view.

FERN Announces Acquisition.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology

SANTA MONICA, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced a global, exclusive licensing agreement providing Opiant access to Aegis’ Intravail® drug delivery technology for all of Opiant’s opioid antagonist compounds. Financial terms were not disclosed.

“We are fortunate to be able to access Aegis’ proprietary Intravail® drug delivery technologies for applications that may benefit patients with addictions and eating disorders,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Aegis’ Intravail® can improve the absorption of drugs delivered nasally and has been designated generally recognized as safe (GRAS).”

Edward T. Maggio, Chief Executive Officer of Aegis added, “The Intravail® non-invasive absorption enhancement technology is particularly well suited for the treatment of chronic relapsing brain diseases and will help ensure that Opiant Pharmaceuticals maintains its leaderhip position in this field. We are excited to support these important programs.”

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

About Aegis Therapeutics  

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Its Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Its ProTek® excipients stabilize, prevent aggregation and reduce unwanted immunogenicity and anaphylaxis of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs. For more information, please visit www.aegisthera.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACT INFORMATION:

Corporate Contact:
Investor.relations@opiant.com

Investors:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902

Source: Opiant Pharmaceuticals, Inc.

            © 2017 GlobeNewswire, Inc.

Pressure BioSciences’ Barocycler 2320EXTREME to be Featured in Multiple Presentations All Week at Major Scientific Meeting

Compelling Advantages of the Company’s Patented PCT Platform Highlighted in Two Different Mass Spectrometry User Meetings on Day One

SOUTH EASTON, MA — (Marketwired) — 06/06/17 — Pressure BioSciences, Inc. (OTCQB: PBIOD) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure cycling technology (“PCT”)-based sample preparation solutions to the worldwide life sciences industry, today announced that the Company’s patented PCT platform will be featured in multiple presentations at the annual conference of the American Society for Mass Spectrometry (“ASMS”), being held from June 4-8, 2017 in Indianapolis, IN.

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: “It is encouraging that in less than one year from the initial shipment of the Barocycler 2320EXT, the advantages of this next-generation PCT-based instrument will be highlighted in multiple presentations by well-respected scientific groups from around the world. These groups include researchers from such noteworthy institutions/companies as the U.S. Food and Drug Administration, Novo Nordisk A/S (Denmark), SCIEX (U.S. and Australia), ETH Zurich (Switzerland), the University of Cologne (Germany), and the Inova Schar Cancer Institute.

Dr. Lawrence continued: “Dr. Thomas Conrads, a nationally-acclaimed protein chemist, is the Associate Director of Scientific Technologies at the Inova Schar Cancer Institute. Dr. Conrads and his group were invited to participate in the SCIEX and ThermoFisher Scientific User Meetings on June 4th. During their presentations, they highlighted the use of the Barocycler 2320EXT for the digestion of tumor and other samples to be analyzed by their group as part of discovery proteomics for the APOLLO Consortium of the Cancer Moonshot program.”

“Proteins comprise most of the biomarkers that are measured to detect cancers, they constitute the antigens that drive immune response and the inter- and intra-cellular communications, and they are the drug targets for nearly every targeted therapy that is being evaluated in cancer trials today,” commented Dr. Conrads. “We believe that a combined systems biology view of the tumor microenvironment that orients cancer studies back to the functional proteome, phosphoproteome, and biochemistry of the cell will be essential to delivering on the promise of the Cancer Moonshot program.”

Dr. Conrads continued: “Standardized, reproducible, high quality preparation of samples to be analyzed is critical to the success of transformative research studies. We spent many months investigating multiple aspects of PCT-enhanced protein extraction and digestion. We subsequently concluded that PCT was an enabling tool that met our high standards for critical sample preparation. We also concluded that the PCT platform could make profiling of our laser micro-dissected tumor tissue samples possible at the throughput required by the APOLLO Consortium of the Cancer Moonshot program.”

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide. At the 2016 ASMS Conference, we unveiled the newest addition to our PCT-based instrument line, the Barocycler 2320EXT. Designed with a number of new and enhanced features and benefits to enable scientists better access to biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, we believe the 2320EXT offers the potential to result in new biological insights and discoveries, and rapid growth for PBI.”

Mr. Schumacher continued: “In February 2017, the Barocycler 2320EXT gained CE Mark approval, enabling it to be marketed throughout all 31 countries in the European Economic Area. In March 2017, the 2320EXT received the 2017 North American Excellence Award for ‘Best New Instrument for Sample Preparation’ by Corporate America News, a leading business publication. The Barocycler 2320EXT has become the centerpiece of our co-marketing agreement with global life sciences analytical technologies leader SCIEX. We believe it will continue to find a significant role in transformative research efforts worldwide, such as the Cancer Moonshot program.”

About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIOD) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 270 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts: Pressure BioSciences, Inc.

Richard T. Schumacher
President & CEO

Nate Lawrence
Vice President of Sales & Marketing

(508) 230-1828 (T)

Source: Pressure BioSciences, Inc.

FERN Announces the Appointment of Omnivance Advisors as Corporate Relations

Fountain Hills, AZ – (May 17, 2017) – Fernhill Corporation. (OTC PINK: FERN), is
pleased to announce the appointment of Omnivance Advisors as head of corporate
relations. Omnivance Advisors will be responsible for increasing the transparency,
credibility and awareness of the company to the investment community.
The Omnivance team will use a comprehensive approach to help maximize the
company’s image as well as shareholder value, utilizing both traditional and
social/media strategies. Mr. Daniel Wong will be considered a key asset in the
establishment and implementation of a proper infrastructure for shareholder
communications.

Fernhill CEO Adam Kovacevic said “In the upcoming weeks there will be many
corporate changes taking place. As part of our strategy we believe that Omnivance
Advisors can help increase the public awareness and maximize shareholder value.
Fernhill looks forward to working closely with Mr. Wong and his team.”
“We are pleased to be selected by Fernhill to deliver a clear and consistent message to
the investment community. During this exciting transition time, our team understands
communication with investors will be critical and look forward to getting the company’s
story disseminated in all channels of distribution. Mr. Kovacevic is committed to
transparency and enhancing shareholder value, which is what we value in our clients.”
commented Daniel Wong, Founder and CEO of Omnivance Advisors, Inc.
Omnivance Advisors will be compensated by Fernhill Corporation using a
predetermined combination of cash and quarterly stock payments.

About the Company: Fernhill Corporation is a natural resource project generation and
royalty business incorporated in Nevada with operations targeted throughout North
America. Fernhill Corporation has been focused on the mining and resources sector
through prospect generation, and the creation and acquisition of royalties.

Safe Harbor Act: Forward-Looking Statements are included within the meaning of
Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements regarding our expected future financial
position, results of operations, cash flows, financing plans, business strategy, products
and services, competitive positions, growth opportunities, plans and objectives of
management for future operations, including words such as “anticipate,” “if,” “believe,”
“plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar
expressions are forward-looking statements and involve risks, uncertainties and
contingencies, many of which are beyond our control, which may cause actual results,
performance, or achievements to differ materially from anticipated results, performance,
or achievements. We are under no obligation to (and expressly disclaim any obligation
to) update or alter our forward-looking statements, whether as a result of new
information, future events or otherwise.

Contact:
Adam Kovacevic
adam@fernhillcorp.com

Contact:
Daniel Wong
Omnivance Advisors, Inc.
Dan@omnivanceadvisors.com
858.381.5740